Summary
The antitumor effects of the camptothecin (CPT) derivative CPT-11, 7-ethyl-10-[4-(1-piperidino)-l-piperidino]-carbonyloxycamptothecin, were tested on human tumor xenografts in nude mice. CPT-11 showed antitumor activity higher than that of Adriamycin, 5-fluorouracil, or futraful, with little or no reduction of body weight being observed in the mice. The growth of colon adenocarcinoma Co-4 was significantly inhibited after a single i.v. injection of CPT-11 at 25, 50, or 100 mg/kg. The single i.v. injection was also significantly effective against mammary carcinoma MX-1 and gastric adenocarcinoma St-15. All of the mice bearing MX-1 tumors were cured by the administration of CPT-11 every 4 days for a total of three treatments at a total dose of 200 mg/kg given i.v. or of 400 mg/kg given p.o. Three i.v. or oral treatments were also effective against Co-4, St-15, gastric adenocarcinoma SC-6, and squamous-cell lung carcinoma QG-56. To achieve the same efficacy attained by i.v.injection, however, oral doses 2–4 times higher than the i.v. doses were required. When the total dose was fixed at 100 mg/kg, a triple i.v. injection was most effective, followed by a single i.v. injection and, finally daily p.o. administration for 10 days. Although SN-38 (7-ethyl-10-hydroxycamptothecin), a metabolite of CPT-11, showed much stronger cytotoxic activity in vitro than did CPT-11, its antitumor effects were similar, if not inferior, to those of CPT-11 in vitro at the same dose level. CPT-11 was converted into SN-38 by human tumors, but the sensitivity of these tumors to CPT-11 in vivo was independent of their ability to produce SN-38. These results suggest that CPT-11 may be clinically effective, depending on the schedule of administration, but that its effectiveness is not related to the ability of the tumor to produce SN-38.
Similar content being viewed by others
References
Bodley AL, Liu LF (1988) Topoisomerases as novel targets for cancer chemotherapy. Biotechnology 6: 1315
Creaven PJ, Allen LM, Muggia FM (1972) Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 56: 573
Drewinko B, Freireich EJ, Gottlieb JA (1974) Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34: 747
Fukuoka M, Negoro S, Niitani H, Taguchi T (1990) A phase II study of a new camptothecin derivative, CPT-11 in previously untreated non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 9: 226
Furuta T, Yokokura T, Mutai M (1978) Antitumor activity of CPT-11 against rat Walker 256 carcinoma. Jpn J Cancer Chemother 15: 2757
Gallo RC, Whang-Peng J, Adamson RH (1971) Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst 46: 789
Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M (1989) DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046
Gottlieb JA, Luce JK (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother Rep 56: 103
Hsiang Y-H, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48: 1722
Hsiang Y-H, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873
Hsiang Y-H, Wu H-Y, Liu LF (1988) Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol 37: 1801
Hsiang Y-H, Lihou MG, Liu LF (1989) Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077
Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res 50: 1715
Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944
Li LH, Fraser TJ, Olin EJ, Bhuyan BK (1972) Action of camptothecin on mammalian cells in culture. Cancer Res 32: 2643
Matsuzaki T, Yokokura T, Mutai M, Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308
Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55
Muggia FM, Creaven PJ, Hansen HH, Cohen MH, Selawry OS (1972) Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56: 515
Rose KM (1988) DNA topoisomerases as targets for chemotherapy. FASEB J 2: 2474
Skipper HE, Schabel FM Jr, Mellett LB, Montgomery JA, Wilkoff LJ, Lloyd HH, Brockman RW (1970) Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54: 431
Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T (1988) Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71
Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA (1966) Plant antitumor agents: 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor fromCamptotheca acuminata. J Am Chem Soc 83: 3888
Wang Y, Inoue K, Shibata H, Itoh Y, Chen SC, Ogawa M (1987) Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay. Jpn J Cancer Chemother 14: 1264
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawato, Y., Furuta, T., Aonuma, M. et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol. 28, 192–198 (1991). https://doi.org/10.1007/BF00685508
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00685508